- Home
- NERV vs MIRA Comparison
NERV vs MIRA Comparison
Compare NERV & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- MIRA
- Stock Information
- Founded
- NERV 2007
- MIRA 2020
- Country
- NERV United States
- MIRA United States
- Employees
- NERV N/A
- MIRA N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- MIRA Health Care
- Exchange
- NERV Nasdaq
- MIRA Nasdaq
- Market Cap
- NERV 18.3M
- MIRA 17.1M
- IPO Year
- NERV 2014
- MIRA 2023
- Fundamental
- Price
- NERV $2.20
- MIRA $1.54
- Analyst Decision
- NERV Hold
- MIRA Strong Buy
- Analyst Count
- NERV 1
- MIRA 2
- Target Price
- NERV $5.00
- MIRA $14.00
- AVG Volume (30 Days)
- NERV 25.3K
- MIRA 3.6M
- Earning Date
- NERV 11-05-2024
- MIRA 11-12-2024
- Dividend Yield
- NERV N/A
- MIRA N/A
- EPS Growth
- NERV N/A
- MIRA N/A
- EPS
- NERV N/A
- MIRA N/A
- Revenue
- NERV N/A
- MIRA N/A
- Revenue This Year
- NERV N/A
- MIRA N/A
- Revenue Next Year
- NERV N/A
- MIRA N/A
- P/E Ratio
- NERV N/A
- MIRA N/A
- Revenue Growth
- NERV N/A
- MIRA N/A
- 52 Week Low
- NERV $2.10
- MIRA $0.51
- 52 Week High
- NERV $13.49
- MIRA $6.40
- Technical
- Relative Strength Index (RSI)
- NERV 34.31
- MIRA 50.38
- Support Level
- NERV $2.26
- MIRA $1.42
- Resistance Level
- NERV $2.43
- MIRA $1.75
- Average True Range (ATR)
- NERV 0.16
- MIRA 0.29
- MACD
- NERV -0.01
- MIRA -0.03
- Stochastic Oscillator
- NERV 13.71
- MIRA 10.53
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.